HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Pipeline

Johnson & Johnson hands back failed eye disease gene therapy to MeiraGTx

After its bet on a rare eye disease gene therapy ended in a phase 3 fail, Johnson & Johnson is returning the asset to sender as MeiraGTx buys back back full rights to botaretigene sparoparvovec (bota-vec) for $25 million upfront.

By FierceBiotech · Apr 17, 2026 · via FierceBiotech
Johnson & Johnson hands back failed eye disease gene therapy to MeiraGTx

Image: FierceBiotech

Tags
pipelineformat:headlineheadlineFierceBiotech
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Pipeline
All Pipeline →
Small pools, big ideas: How the rare disease community is reimagining clinical trials
PipelineFierceBiotech ↗
Small pools, big ideas: How the rare disease community is reimagining clinical trials
The traditional gold standard of clinical trials with a randomized, placebo-controlled design involving hundre…
Apr 17, 2026
Qiagen launches latest diagnostic for bloodstream infections
PipelineFierceBiotech ↗
Qiagen launches latest diagnostic for bloodstream infections
Qiagen has moved into syndromic testing for bloodstream infections with the launch of its newest offering.…
Apr 17, 2026
Labcorp launches rapid fentanyl test with 48-hour detection window
PipelineFierceBiotech ↗
Labcorp launches rapid fentanyl test with 48-hour detection window
While fentanyl overdose deaths have been falling in recent years, use of the drug remains a major public healt…
Apr 17, 2026